

## **I. AMENDMENT TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **LISTING OF CLAIMS**

Claim 1. (previously presented) A method of effectively treating hypertension, angina, or both conditions in a human patient, comprising:

administering felodipine transdermally to the human patient by applying a transdermal delivery system containing felodipine to the skin of the patient, and maintaining said transdermal delivery system in contact with the skin of said patient for at least 3 days, said transdermal delivery system maintaining an effective mean relative release rate to provide a therapeutic blood level of said felodipine within 36 hours from the initiation of the dosing interval, and thereafter maintaining a therapeutic blood level until the end of at least the three-day dosing interval,

said transdermal delivery system having a mean relative release rate of from about  $4.2 \mu\text{g}/\text{cm}^2/\text{hr}$  to about  $20.0 \mu\text{g}/\text{cm}^2/\text{hr}$  at 24 hours;

from about  $3.3 \mu\text{g}/\text{cm}^2/\text{hr}$  to about  $14.0 \mu\text{g}/\text{cm}^2/\text{hr}$  at 48 hours; and

from about  $2.7 \mu\text{g}/\text{cm}^2/\text{hr}$  to about  $10.8 \mu\text{g}/\text{cm}^2/\text{hr}$  at 72 hours; as determined via an in-vitro permeation test utilizing a Valia-Chien cell where the membrane is a human cadaver skin and said cell has a receptor chamber containing a 40:60 mixture of Ethanol:water;

said transdermal delivery system providing a mean relative release rate of felodipine to provide a plasma level of felodipine of at least 0.1 ng/ml within about 6 hours after application of said transdermal delivery system onto the skin of said patient.

Claim 2. (canceled)

Claim 3. (original) The method of claim 1, further comprising maintaining a plasma level of felodipine at steady-state from about 1.0 to about 3.0 ng/ml.